Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection

INTRODUCTION: There are limited data on the effect and evolution of risk factors for hepatocellular carcinoma (HCC) in patients with virologically cured hepatitis C virus (HCV) infection. METHODS: We conducted a retrospective cohort study of patients with HCV who achieved sustained virological response with direct-acting antivirals from 130 Veterans Administration hospitals during 2014–2018, followed through 2021. Cox proportional hazards models were constructed at 3 landmark times (baseline and 12 and 24 months after sustained virological response) to examine associations between demographic, clinical, and behavioral factors and HCC risk, stratified by cirrhosis status. RESULTS: Among 92,567 patients (32% cirrhosis), 3,247 cases of HCC were diagnosed during a mean follow-up of 2.5 years. In patients with cirrhosis, male sex (hazard ratios [HR]: 1.89, 1.93, and 1.99), cirrhosis duration ≥5 years (HR: 1.71, 1.79, and 1.34), varices (HR: 1.73, 1.60, and 1.56), baseline albumin (HR: 0.48, 0.47, and 0.49), and change in albumin (HR: 0.82 and 0.90) predicted HCC risk at each landmark time. HCV genotype 3, previous treatment, bilirubin, smoking, and race influenced HCC risk at baseline, but their effects attenuated over time. In patients without cirrhosis, diabetes (HR: 1.54, 1.42, and 1.47) and hypertension (HR: 1.59, 1.65, and 1.74) were associated with HCC risk at all landmark times. Changes in fibrosis-4 scores over time were associated with HCC risk both in patients with and without cirrhosis. DISCUSSION: Risk factors for HCC were different in patients with and without cirrhosis and some also evolved during follow-up. These factors can help with risk stratification and HCC surveillance decisions in patients with cured HCV.

[1]  R. Chaiteerakij,et al.  Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis , 2021, World journal of hepatology.

[2]  T. Ayer,et al.  Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents , 2020, JAMA network open.

[3]  N. Shackel,et al.  Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. , 2020, Hepatobiliary & pancreatic diseases international : HBPD INT.

[4]  Zhichao Feng,et al.  Sarcopenia associates with increased risk of hepatocellular carcinoma among male patients with cirrhosis. , 2020, Clinical nutrition.

[5]  S. Asch,et al.  Long‐Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents , 2020, Hepatology.

[6]  R. Sterling,et al.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores. , 2019, Gastroenterology.

[7]  K. Kerr,et al.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. , 2018, Journal of hepatology.

[8]  N. Weiss,et al.  No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. , 2018, Gastroenterology.

[9]  H. Hong,et al.  Association between cotinine‐verified smoking status and risk of nonalcoholic fatty liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[10]  S. Asch,et al.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.

[11]  Yu Xu,et al.  Active Smoking, Passive Smoking, and Risk of Nonalcoholic Fatty Liver Disease (NAFLD): A Population-Based Study in China , 2013, Journal of epidemiology.

[12]  H. Putter,et al.  Dynamic Prediction in Clinical Survival Analysis , 2011 .

[13]  U. Dafni Landmark Analysis at the 25-Year Landmark Point , 2011, Circulation. Cardiovascular quality and outcomes.

[14]  A. McCullough,et al.  Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. , 2011, Journal of hepatology.

[15]  Angelique Zeringue,et al.  Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. , 2011, Gastroenterology.

[16]  K. Straif,et al.  Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. , 2009, International journal of epidemiology.

[17]  Ewout W. Steyerberg,et al.  Prognostic Models With Competing Risks: Methods and Application to Coronary Risk Prediction , 2009, Epidemiology.

[18]  H. El‐Serag,et al.  Utilization of Screening for Hepatocellular Carcinoma in the United States , 2007 .

[19]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[20]  D. Kivlahan,et al.  Implementation of evidence-based alcohol screening in the Veterans Health Administration. , 2006, The American journal of managed care.

[21]  Peter J. Richardson,et al.  The Effect of HIV Coinfection on the Risk of Cirrhosis and Hepatocellular Carcinoma in U.S. Veterans with Hepatitis C , 2005, The American Journal of Gastroenterology.